First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Background: Malaria in pregnancy has major impacts on mother and child health. To complement existing interventions, such as intermittent preventive treatment and use of impregnated bed nets, we developed a malaria vaccine candidate with the aim of reducing sequestration of asexual “blood-stage” parasites in the placenta, the major virulence mechanism. Methods: The vaccine candidate PAMVAC is based on a recombinant fragment of VAR2CSA, the Plasmodium falciparum protein responsible for binding to the placenta via chondroitin sulfate A (CSA). Healthy, adult malaria-naive volunteers were immunized with 3 intramuscular injections of 20 μg (n = 9) or 50 μg (n = 27) PAMVAC, adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) or in a liposomal formulation with QS21 (GLA-LSQ). Allocation was random and double blind. The vaccine was given every 4 weeks. Volunteers were observed for 6 months following last immunization. Results: All PAMVAC formulations were safe and well tolerated. A total of 262 adverse events (AEs) occurred, 94 (10 grade 2 and 2 grade 3) at least possibly related to the vaccine. No serious AEs occurred. Distribution and severity of AEs were similar in all arms. PAMVAC was immunogenic in all participants. PAMVAC-specific antibody levels were highest with PAMVAC-GLA-SE. The antibodies inhibited binding of VAR2CSA expressing P. falciparum-infected erythrocytes to CSA in a standardized functional assay. Conclusions: PAMVAC formulated with Alhydrogel or GLA-based adjuvants was safe, well tolerated, and induced functionally active antibodies. Next, PAMVAC will be assessed in women before first pregnancies in an endemic area. Clinical Trials Registration: EudraCT 2015-001827-21; ClinicalTrials.gov NCT02647489.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two VAR2CSA N-terminal subunits containing the minimal CSA-binding fragment [5] have been tested in Phase I clinical trials [6,7] but did not induce strain-transcending neutralizing immunoglobulin G (IgG).”
From A conformational epitope in placental malaria vaccine antigen VAR2CSA: What does it teach us? (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Antibody to PAM1.4-like strain-transcending epitopes may fail to be induced by VAR2CSA subunit immunogens (Fig 1D), as seen in humans immunized with VAR2CSA fragments who mounted limited serum functional activity against heterologous strains [6,7].”
From A conformational epitope in placental malaria vaccine antigen VAR2CSA: What does it teach us? (2023) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The pathogenic basis of malaria
Miller, L. H., Baruch, D. I., Marsh, K., & Doumbo, O. K. (2002) · Nature · doi:10.1038/415673a · Cited by 1,746
Su, X.-Z., Heatwole, V. M., Wertheimer, S. P., Guinet, F., Herrfeldt, J. A., Peterson, D. S., Ravetch, J. A., & Wellems, T. E. (1995) · Cell · doi:10.1016/0092-8674(95)90055-1 · Cited by 1,219
Baruch, D. I., Pasloske, B. L., Singh, H. B., Bi, X., Ma, X. C., Feldman, M., Taraschi, T. F., & Howard, R. J. (1995) · Cell · doi:10.1016/0092-8674(95)90054-3 · Cited by 1,030
Self-citationSalanti, A., Staalsoe, T., Lavstsen, T., Jensen, A. T. R., Sowa, M. P. K., Arnot, D. E., Hviid, L., & Theander, T. G. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03570.x · Cited by 702 · cited 1×
“1510 • cid 2019:69 (1 November) • Mordmüller et al form of chondroitin sulfate A (CSA) [8].”
BackgroundSelf-citationMaternal antibodies block malaria
Fried, M., Nosten, F., Brockman, A., Brabin, B. J., & Duffy, P. E. (1998) · Nature · doi:10.1038/27570 · Cited by 659
Bull, P. C., Lowe, B. S., Kortok, M., Molyneux, C. S., Newbold, C. I., & Marsh, K. (1998) · Nature Medicine · doi:10.1038/nm0398-358 · Cited by 645
Malaria in pregnancy: pathogenesis and immunity
Rogerson, S. J., Hviid, L., Duffy, P. E., Leke, R. F., & Taylor, D. W. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70022-1 · Cited by 628
Evidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria
Salanti, A., Dahlbäck, M., Turner, L., Nielsen, M. A., Barfod, L., Magistrado, P., Jensen, A. T. R., Lavstsen, T., Ofori, M. F., Marsh, K., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041579 · Cited by 604
Self-citationAntigens Induced on Erythrocytes by P. falciparum : Expression of Diverse and Conserved Determinants
Marsh, K., & Howard, R. J. (1986) · Science · doi:10.1126/science.2417315 · Cited by 322
Self-citationRicke, C. H., Staalsoe, T., Koram, K., Akanmori, B. D., Riley, E. M., Theander, T. G., & Hviid, L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.6.3309 · Cited by 303
Self-citationDuffy, P. E., & Fried, M. (2003) · Infection and Immunity · doi:10.1128/iai.71.11.6620-6623.2003 · Cited by 260 · cited 1×
“The main mechanism of protection is interference with iRBCs binding to placental CSA [10, 18].”
BackgroundNielsen, M. A., Staalsoe, T., Kurtzhals, J. A. L., Goka, B. Q., Dodoo, D., Alifrangis, M., Theander, T. G., Akanmori, B. D., & Hviid, L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3444 · Cited by 207
Self-citationBacterial superglue enables easy development of efficient virus-like particle based vaccines
Thrane, S., Janitzek, C. M., Matondo, S., Resende, M., Gustavsson, T., de Jongh, W. A., Clemmensen, S., Roeffen, W., van de Vegte‑Bolmer, M., van Gemert, G. J., et al. (2016) · Journal of Nanobiotechnology · doi:10.1186/s12951-016-0181-1 · Cited by 203
Self-citationMalaria prevention: from immunological concepts to effective vaccines and protective antibodies
Cockburn, I. A., & Seder, R. A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0228-6 · Cited by 166
Moore, K. A., Simpson, J. A., Scoullar, M. J. L., McGready, R., & Fowkes, F. J. I. (2017) · The Lancet Global Health · doi:10.1016/s2214-109x(17)30340-6 · Cited by 165 · cited 1×
“VAR2CSA, mediates binding to a distinct placenta-specific applyparastyle “fig//caption/p[1]” parastyle “FigCapt””
BackgroundRecent advances in recombinant protein-based malaria vaccines
Draper, S. J., Angov, E., Horii, T., Miller, L. H., Srinivasan, P., Theisen, M., & Biswas, S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.093 · Cited by 138
Virus-like particle display of HER2 induces potent anti-cancer responses
Palladini, A., Thrane, S., Janitzek, C. M., Pihl, J., Clemmensen, S. B., de Jongh, W. A., Clausen, T. M., Nicoletti, G., Landuzzi, L., Penichet, M. L., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1408749 · Cited by 129
Self-citationAyres Pereira, M., Mandel Clausen, T., Pehrson, C., Mao, Y., Resende, M., Daugaard, M., Riis Kristensen, A., Spliid, C., Mathiesen, L., E. Knudsen, L., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005831 · Cited by 105
Self-citationProtective Antibodies against Placental Malaria and Poor Outcomes during Pregnancy, Benin
Ndam, N. T., Denoeud-Ndam, L., Doritchamou, J., Viwami, F., Salanti, A., Nielsen, M. A., Fievet, N., Massougbodji, A., Luty, A. J. F., & Deloron, P. (2015) · Emerging Infectious Diseases · doi:10.3201/eid2105.141626 · Cited by 98
Self-citationDynamics of Anti‐VAR2CSA Immunoglobulin G Response in a Cohort of Senegalese Pregnant Women
Tuikue Ndam, N. G., Salanti, A., Le‐Hesran, J. ‐., Cottrell, G., Fievet, N., Turner, L., Sow, S., Dangou, J. ‐., Theander, T., & Deloron, P. (2006) · The Journal of Infectious Diseases · doi:10.1086/500146 · Cited by 89
Self-citationVAR2CSA and protective immunity against pregnancy-associated Plasmodium falciparum malaria
HVIID, L., & SALANTI, A. (2007) · Parasitology · doi:10.1017/s0031182007000121 · Cited by 69
Self-citationHigh Avidity Antibodies to Full-Length VAR2CSA Correlate with Absence of Placental Malaria
Tutterrow, Y. L., Salanti, A., Avril, M., Smith, J. D., Pagano, I. S., Ako, S., Fogako, J., Leke, R. G. F., & Taylor, D. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040049 · Cited by 67
Self-citationBarfod, L., Dobrilovic, T., Magistrado, P., Khunrae, P., Viwami, F., Bruun, J., Dahlbäck, M., Bernasconi, N. L., Fried, M., John, D., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002390 · Cited by 62
Self-citationPlasmodium falciparum Infection Early in Pregnancy has Profound Consequences for Fetal Growth
Schmiegelow, C., Matondo, S., Minja, D. T. R., Resende, M., Pehrson, C., Nielsen, B. B., Olomi, R., Nielsen, M. A., Deloron, P., Salanti, A., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix530 · Cited by 53
Self-citationNielsen, M. A., Resende, M., de Jongh, W. A., Ditlev, S. B., Mordmüller, B., Houard, S., Ndam, N. T., Agerbæk, M. Ø., Hamborg, M., Massougbodji, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135406 · Cited by 48
Self-citationMayor, A., Kumar, U., Bardají, A., Gupta, P., Jiménez, A., Hamad, A., Sigaúque, B., Singh, B., Quintó, L., Kumar, S., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit083 · Cited by 45
Multilaboratory Approach to Preclinical Evaluation of Vaccine Immunogens for Placental Malaria
Fried, M., Avril, M., Chaturvedi, R., Fernandez, P., Lograsso, J., Narum, D., Nielsen, M. A., Oleinikov, A. V., Resende, M., Salanti, A., et al. (2013) · Infection and Immunity · doi:10.1128/iai.01106-12 · Cited by 38
Self-citationFernandez, P., Petres, S., Mécheri, S., Gysin, J., & Scherf, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012558 · Cited by 36
Correlating efficacy and immunogenicity in malaria vaccine trials
McCall, M. B. B., Kremsner, P. G., & Mordmüller, B. G. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.08.002 · Cited by 32
Self-citationDechavanne, S., Srivastava, A., Gangnard, S., Nunes-Silva, S., Dechavanne, C., Fievet, N., Deloron, P., Chêne, A., & Gamain, B. (2015) · Infection and Immunity · doi:10.1128/iai.03116-14 · Cited by 31
Self-citationDeveloping vaccines to prevent malaria in pregnant women
Ndam, N. T., & Deloron, P. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1049595 · Cited by 30
Self-citationDoritchamou, J., Bigey, P., Nielsen, M. A., Gnidehou, S., Ezinmegnon, S., Burgain, A., Massougbodji, A., Deloron, P., Salanti, A., & Ndam, N. T. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.072 · Cited by 29
Self-citationGbédandé, K., Fiévet, N., Viwami, F., Ezinmègnon, S., Issifou, S., Chippaux, J., Dossou, Y. A., Moutairou, K. A., Massougbodji, A., Ndam, N. T., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.05.027 · Cited by 27
Self-citationBrolin, K. J. M., Persson, K. E. M., Wahlgren, M., Rogerson, S. J., & Chen, Q. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009230 · Cited by 24
Template protocol for clinical trials investigating vaccines—Focus on safety elements
Bonhoeffer, J., Imoukhuede, E. B., Aldrovandi, G. M., Bachtiar, N. S., Chan, E.-S., Chang, S., Chen, R. T., Fernandopulle, R., Goldenthal, K. L., Heffelfinger, J. D., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.041 · Cited by 23
Doritchamou, J., Sabbagh, A., Jespersen, J. S., Renard, E., Salanti, A., Nielsen, M. A., Deloron, P., & Tuikue Ndam, N. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137695 · Cited by 22
Self-citationPinto, V. V., Ditlev, S. B., Jensen, K. E., Resende, M., Dahlbäck, M., Andersen, G., Andersen, P., Theander, T. G., Salanti, A., & Nielsen, M. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017942 · Cited by 18
Self-citationComparison of functional assays used in the clinical development of a placental malaria vaccine
Pehrson, C., Heno, K. K., Adams, Y., Resende, M., Mathiesen, L., Søgaard, M., de Jongh, W. A., Theander, T. G., Salanti, A., & Nielsen, M. A. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.12.028 · Cited by 13
Self-citationHigh-Throughput Testing of Antibody-Dependent Binding Inhibition of Placental Malaria Parasites
Nielsen, M. A., & Salanti, A. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2815-6_20 · Cited by 12
Self-citation
Cited by
Frederiksen, L. S. F., Zhang, Y., Foged, C., & Thakur, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01817 · Cited by 287
Malaria vaccines since 2000: progress, priorities, products
Duffy, P. E., & Patrick Gorres, J. (2020) · npj Vaccines · doi:10.1038/s41541-020-0196-3 · Cited by 266
New insights into malaria pathogenesis
Moxon, C. A., Gibbins, M. P., McGuinness, D., Milner, D. A., & Marti, M. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032640 · Cited by 207
“The unique conservation of this PfEMP1 variant, its specific function, and the existence of natural protective immunity make VAR2CSA a prime candidate for a malaria subunit vaccine (146, 147).”
BackgroundSirima, S. B., Richert, L., Chêne, A., Konate, A. T., Campion, C., Dechavanne, S., Semblat, J.-P., Benhamouda, N., Bahuaud, M., Loulergue, P., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30739-x · Cited by 124
Self-citationStructural basis for placental malaria mediated by Plasmodium falciparum VAR2CSA.
Ma, R., Lian, T., Huang, R., Renn, J. P., Petersen, J. D., Zimmerberg, J., Duffy, P. E., & Tolia, N. H. (2021) · Nature Microbiology · doi:10.1038/s41564-020-00858-9 · Cited by 72
Metadata
- Authors
- Mordmüller, B., Sulyok, M., Egger-Adam, D., Resende, M., de Jongh, W. A., Jensen, M. H., Smedegaard, H. H., Ditlev, S. B., Soegaard, M., Poulsen, L., Dyring, C., Calle, C. L., Knoblich, A., Ibáñez, J., Esen, M., Deloron, P., Ndam, N., Issifou, S., Houard, S., Howard, R. F., Reed, S. G., Leroy, O., Luty, A. J. F., Theander, T. G., Kremsner, P. G., Salanti, A., & Nielsen, M. A.
- Affiliations
- Universitätsklinikum Tübingen (DE)
- Institut für Tropenmedizin, Universitätsklinikum Tübingen and Deutsches Zentrum für Infektionsforschung, Germany
- University of Copenhagen (DK)
- ExpreS2ion Biotechnologies, Horsholm, Denmark
- Centre for Medical Parasitology at Department of Immunology and Microbiology, University of Copenhagen and Department of Infectious Diseases, Copenhagen University Hospital
- ExpreS2ion Biotechnologies (Denmark) (DK)
- Sorbonne Paris Cité (FR)
- Institut de Recherche Clinique du Bénin (BJ)
- European Vaccine Initiative (DE)
- Infectious Disease Research Institute (US)
- Corresponding author
- Nielsen, Morten A
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01-10
- Volume
- 69
- Issue
- 9
- Pages
- 1509-1516
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC6792113
- OpenAlex
- W2910623818
- Cited by
- 154
- References
- 39
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 21 · 2023: 17 · 2022: 27 · 2021: 38 · 2020: 21 · 2019: 8
- FWCI
- 21.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Infectious Diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Funders
- European Union in the Seventh Framework Programme (FP7-HEALTH-2012-INNOVATION, 304815)
- German Federal Ministry of Education and Research
- Danish Advanced Technology Foundation (005-2011-1)
- Bill and Melinda Gates Foundation (42387, OPP1055855)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- malaria in pregnancy, malaria vaccine, VAR2CSA, Plasmodium falciparum, placental sequestration, chondroitin sulfate A, Alhydrogel adjuvant, vaccine safety, immunogenicity, antibody binding inhibition, malaria-naive volunteers
- MeSH terms
- Adult, Aluminum Hydroxide, Chondroitin Sulfates, Double-Blind Method, Female, Humans, Injections, Intramuscular, Liposomes, Plasmodium falciparum, Pregnancy, Malaria Vaccines, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.